

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

NCT05646381

Status	RECRUITING
Phase	Phase 2
Sponsor	Novartis Pharmaceuticals
Enrollment	502 participants

Key Eligibility Criteria

Inclusion (4)

- Male and female e50 to \<80 years of age at Screening Part II
- Lp(a) e175 nmol/L at the screening visit, measured at the Central laboratory
- Mild or moderate calcific aortic valve stenosis
- At the randomization visit, participant must be optimally treated for existing CV risk factors

Exclusion (8)

- Severe calcific aortic valve stenosis
- Uncontrolled hypertension
- History of malignancy of any organ system
- History of hemorrhagic stroke or other major bleeding
- Platelet count d LLN

... and 3 more (see full listing online)

Locations (136 total)

Heart Center Research Llc, Huntsville, Alabama, United States
Cardiovascular Res Found, Beverly Hills, California, United States
National Heart Institute, Beverly Hills, California, United States
... and 133 more locations